scholarly journals Effects of diltiazem on plasma uric acid level and renal uric acid excretion in rats.

1989 ◽  
Vol 50 (2) ◽  
pp. 239-242 ◽  
Author(s):  
Haruko SUGINO ◽  
Hideyo SHIMADA
Keyword(s):  
Uric Acid ◽  
Uric Acid Level ◽  
Acid Level ◽  
Acid Excretion ◽  
Uric Acid Excretion ◽  
Plasma Uric Acid

scholarly journals The Time-Feature of Uric Acid Excretion in Hyperuricemia Mice Induced by Potassium Oxonate and Adenine

2020 ◽  
Vol 21 (15) ◽  
pp. 5178
Author(s):  
Shaoshi Wen ◽  
Dan Wang ◽  
Haiyang Yu ◽  
Mengyang Liu ◽  
Qian Chen ◽  
...  
Keyword(s):  
Renal Function ◽  
Uric Acid ◽  
Mouse Model ◽  
Uric Acid Level ◽  
Acid Level ◽  
Acid Excretion ◽  
Mice Model ◽  
Uric Acid Excretion ◽  
Plasma Uric Acid ◽  
Potassium Oxonate

Hyperuricemia is an important risk factor of chronic kidney disease, metabolic syndrome and cardiovascular disease. We aimed to assess the time-feature relationship of hyperuricemia mouse model on uric acid excretion and renal function. A hyperuricemia mouse model was established by potassium oxonate (PO) and adenine for 21 days. Ultra Performance Liquid Chromatography was used to determine plasma uric acid level. Hematoxylin-eosin staining was applied to observe kidney pathological changes, and Western blot was used to detect renal urate transporters’ expression. In hyperuricemia mice, plasma uric acid level increased significantly from the 3rd day, and tended to be stable from the 7th day, and the clearance rate of uric acid decreased greatly from the 3rd day. Further study found that the renal organ of hyperuricemia mice showed slight damage from the 3rd day, and significantly deteriorated renal function from the 10th day. In addition, the expression levels of GLUT9 and URAT1 were upregulated from the 3rd day, while ABCG2 and OAT1 were downregulated from the 3rd day, and NPT1 were downregulated from the 7th day in hyperuricemia mice kidney. This paper presents a method suitable for experimental hyperuricemia mouse model, and shows the time-feature of each index in a hyperuricemia mice model.

scholarly journals The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor

2019 ◽  
Vol 24 (S1) ◽  
pp. 92-102
Author(s):  
Daisuke Okui ◽  
Tomomitsu Sasaki ◽  
Masahiko Fushimi ◽  
Tetsuo Ohashi
Keyword(s):  
Uric Acid ◽  
Serum Uric Acid ◽  
Uric Acid Level ◽  
Acid Level ◽  
Serum Uric Acid Level ◽  
Combination Group ◽  
Acid Excretion ◽  
Uric Acid Excretion ◽  
Percent Change ◽  
Urate Reabsorption

Abstract Background Dotinurad, a novel selective urate reabsorption inhibitor (SURI), increases urinary uric acid excretion. The aim of this study is to examine the pharmacokinetics, pharmacodynamics, and safety of dotinurad according to the type of hyperuricemia, with or without concomitant use of xanthine oxidase inhibitor, in uric acid “overproduction type” patients. Methods This open-label clinical pharmacology study was conducted in a hospital. Dotinurad 1 mg was administered for 7 days to hyperuricemic patients with uric acid “overproduction type” (overproduction group, n = 6; and combination group, n = 6) and uric acid “underexcretion type” (underexcretion group, n = 6). In the combination group, topiroxostat 80 mg was used concomitantly. Results No significant differences were observed in pharmacokinetics and safety between overproduction group and underexcretion group, and the percent change in serum uric acid level and the amount of urinary uric acid excretion after administration were comparable. In “overproduction type” patients of combination group, the percent change in serum uric acid level significantly increased and the amount of urinary uric acid excretion significantly decreased compared to those of overproduction group. No clinically meaningful differences were observed in safety between the overproduction group and the combination group. Conclusion In inpatients, differences in hyperuricemic type did not significantly influence the pharmacokinetics, pharmacodynamics, and safety of dotinurad. Moreover, in “overproduction type”, the coadministration of dotinurad and topiroxostat had an add-on serum uric acid lowering effect and suppressed urinary uric acid excretion. Trial registration ClinicalTrials.gov Identifier: NCT02837198.

Blood Uric Acid Level and IQ: A Study in Twin Families

1984 ◽  
Vol 33 (2) ◽  
pp. 237-242 ◽  
Author(s):  
E. Inouye ◽  
K.S. Park ◽  
A. Asaka
Keyword(s):  
Uric Acid ◽  
Uric Acid Level ◽  
Quantitative Traits ◽  
Acid Level ◽  
Genetic Basis ◽  
Plasma Uric Acid ◽  
Blood Uric Acid ◽  
Twin Children ◽  
Twin Families ◽  
Familial Environment

AbstractApplying newly devised model, heritability (VA/VP) of plasma uric acid level, corrected for age and sex and standardized, was estimated at 0.8 in families consisting of twin parents, spouses and children. Correlation between spouses due to common genotype (ρ) was approximately 0.1, and variance due to common familial environment (VEC/Vp) was -0.3. Analysis of families of selected twin children and their parents resulted in two estimates of heritability: approximately 0.7 and 0.3, ρ being 0.34 and 0.04, and VEC/Vp being 0.04 and 0.34, respectively. Regression of IQ (y) on corrected and standardized plasma uric acid level (x) in the twin children was y = 5.56x + 123, correlation being 0.334 (p < 0.025). The result indicates a genetic basis of blood uric acid level, which may have resulted from polymorphisms in purine metabolism pathway, end product of which is uric acid in man. The significant correlation between plasma uric acid level and IQ suggests a contribution of partly common gene loci to the two quantitative traits.

Clinical Implication of Plasma Uric Acid Level

2009 ◽  
Vol 30 (9) ◽  
pp. 670 ◽  
Author(s):  
Young Tae Shin ◽  
Kyoung Kon Kim ◽  
In Cheol Hwang
Keyword(s):  
Uric Acid ◽  
Uric Acid Level ◽  
Clinical Implication ◽  
Acid Level ◽  
Plasma Uric Acid

scholarly journals A higher baseline plasma uric acid level is an independent predictor of arterial stiffness

Medicine ◽  
2017 ◽  
Vol 96 (6) ◽  
pp. e5957 ◽  
Author(s):  
Xiao-Han Ding ◽  
Xiaona Wang ◽  
Ruihua Cao ◽  
Xu Yang ◽  
Wenkai Xiao ◽  
...  
Keyword(s):  
Uric Acid ◽  
Arterial Stiffness ◽  
Uric Acid Level ◽  
Acid Level ◽  
Independent Predictor ◽  
Plasma Uric Acid

Low plasma uric acid level in Parkinson's disease

2007 ◽  
Vol 22 (8) ◽  
pp. 1133-1137 ◽  
Author(s):  
Tua Annanmaki ◽  
Antti Muuronen ◽  
Kari Murros
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Uric Acid ◽  
Uric Acid Level ◽  
Acid Level ◽  
Plasma Uric Acid

scholarly journals Plasma Uric Acid Level and Risk for Incident Hypertension Among Men

2006 ◽  
Vol 18 (1) ◽  
pp. 287-292 ◽  
Author(s):  
John P. Forman ◽  
Hyon Choi ◽  
Gary C. Curhan
Keyword(s):  
Uric Acid ◽  
Uric Acid Level ◽  
Acid Level ◽  
Incident Hypertension ◽  
Plasma Uric Acid
Sign in / Sign up

Export Citation Format

Share Document